Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.

摘要: The treatment paradigm in advanced renal cell carcinoma (RCC) has changed the recent years. Sunitinib been established as a new standard for first-line therapy. We studied prognostic significance of baseline characteristics and we compared risk stratification with Memorial Sloan Kettering Cancer Center (MSKCC) model. This is retrospective analysis patients treated six Greek Oncology Units HECOG. Inclusion criteria were: not amenable to surgery Sunitinib. Previous cytokine therapy but no targeted agents were allowed. Overall survival (OS) was major end point. Significance factors evaluated multivariate cox regression analysis. A model developed stratify according risk. One hundred nine included. Median follow up 15.8 months median OS 17.1 (95% CI: 13.7-20.6). Time from diagnosis start ( 12 months, p = 0.001), number metastatic sites (1 vs. >1, 0.003) performance status (PS) 1, 0.001) independently associated OS. Stratification two groups ("low" risk: 0 or 1 factors; "high" 2 3 factors) resulted distinctly different (median reached [NR] 10.8 [95% confidence interval (CI): 8.3-13.3], < 0.001). application MSKCC into (low intermediate poor risk) prognosis underlying its validity. Nevertheless, did show an improved over by this Studies on RCC therapies are warranted. Our results suggest that simpler than can be developed. Such models should further validated.